|
Guter Punkt. Dass es dazu keine PM gab, ist echt nicht geil.
Ich hab jetzt aber noch mal das Filing etwas genauer angeschaut und das Problem gefunden:
As described above, because the proposed Authorized Share Reduction represents only a 50% reduction in our authorized shares of common stock and the Reverse Stock Split represents a four-fold reduction in our issued and outstanding common stock, the net effect of Proposals 1 and 2 will be to increase the number of shares of common stock available for issuance. However, the Board believes that the 1-for-4 reverse split ratio will appropriately balance the needs for available shares for capital raising, strategic transactions, and equity incentive awards with the desire to avoid having an unreasonably high number of authorized shares. The Board believes that the size of the increase in available shares is appropriate to provide for our long-term needs and is in line with most mature companies.
Effektiv wird also tatsächlich die Anzahl der authorized shares erhöht, was eine Verwässerung der vorhanden Aktien ist, aber natürlich "nur" im Rahmen wie das sonst auch passiert, wenn neue Aktien als Kapitalmaßnahme ausgegeben werden.
Zahlen für Q1/21
the Company believes will be sufficient to fund the Company’s operating expenses and capital expenditure requirements through the fourth quarter of 2022.
www.trevena.com/investors/press-releases/...rter-2021-results
Zahlen für Q2/21
OLINVYK respiratory physiology study currently enrolling, topline data expected by YE 2021
www.trevena.com/investors/press-releases/...rter-2021-results
Sieht auf dem ersen Blick vielversprechend aus.
92% probability that TRV027 has a potential beneficial impact on primary endpoint of D-dimer levels, a biomarker associated with critical illness and mortality
~12 days lower average hospital length of stay in patients treated with TRV027 compared to placebo
Quelle: Trevena Announces Results of TRV027 Proof-of-Concept Study in COVID-19 Patients
TRV027 is currently being evaluated in a randomized controlled study (NIH ACTIV-4) and a global adaptive platform study (REMAP-CAP)
TRV027 is a novel AT1 receptor selective agonist with the potential to treat acute lung damage / abnormal blood clotting associated with COVID-19
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
6 | 916 | Trevena - biopharmaceutical company +69,67 % | Balu4u | Dölauer | 19.07.23 17:35 | |
Nach dem Split | Dölauer | 11.11.22 12:44 | ||||
176 | Trevena FDA 2018 Olinvo | OlliCash | joker75 | 25.04.21 00:44 |